Sunphenon ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica4
113Muscular dystrophy2

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00799890
(ClinicalTrials.gov)
May 200928/11/2008Sunphenon in Progressive Forms of Multiple SclerosisMonocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple SclerosisMultiple SclerosisDrug: Sunphenon EGCG;Drug: PlaceboFriedemann PaulTAIYO EUROPECompleted18 Years65 YearsAll61Phase 2/Phase 3Germany
2NCT00525668
(ClinicalTrials.gov)
September 20074/9/2007Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)Relapsing-remitting Multiple SclerosisDrug: epigallocatechin-gallate (Sunphenon);Drug: placeboCharite University, Berlin, GermanyNULLCompleted18 Years60 YearsAll120Phase 1/Phase 2Germany
3EUCTR2006-006323-39-DE
(EUCTR)
19/06/200705/03/2007Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MSSunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS relapsing-remitting multiple sclerosisICD classification: G35.1Product Name: Sunphenon
Other descriptive name: Sunphenon EGCg TM
Charité-Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
100Germany
4EUCTR2008-005213-22-DE
(EUCTR)
22/08/2008SUPREMES - Sunphenon in progressive forms of multiple sclerosisSUPREMES - Sunphenon in progressive forms of multiple sclerosis - SUPREMES primary and secondary progressive forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Sunphenon
Other descriptive name: Sunphenon EGCg
Charite Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
60Phase 2;Phase 3Germany

113. Muscular dystrophy


Clinical trials : 646 Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01183767
(ClinicalTrials.gov)
December 30, 201017/8/2010Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular DystrophySunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: Epigallocatechin-Gallate;Drug: PlaceboCharite University, Berlin, GermanyNULLCompleted5 Years10 YearsAll33Phase 2/Phase 3Germany
2EUCTR2009-016482-28-DE
(EUCTR)
25/06/201015/03/2010SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular DystrophySUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy - SUNIMUD Duchenne Muscular Dystrophy;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Product Name: Sunphenon EGCG
INN or Proposed INN: Sunphenon
Charite Universitätsmedizin BerlinNULLNot RecruitingFemale: no
Male: yes
40Phase 2Germany